Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study
- 24 June 2022
- journal article
- research article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (9) , 2378-2385
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- GlaxoSmithKline
- Amgen
- AbbVie
- Bristol-Myers Squibb
- Regeneron Pharmaceuticals
- Eli Lilly and Company
- UCB
- Pediatric Dermatology Research Alliance
- Genzyme
- AstraZeneca
This publication has 39 references indexed in Scilit:
- Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statementBritish Journal of Dermatology, 2018
- Public Health Burden and Epidemiology of Atopic DermatitisDermatologic Clinics, 2017
- Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT surveyJournal of the American Academy of Dermatology, 2017
- Persistence of atopic dermatitis (AD): A systematic review and meta-analysisJournal of the American Academy of Dermatology, 2016
- Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adultsBritish Journal of Dermatology, 2016
- Atopic Dermatitis: Global Epidemiology and Risk FactorsAnnals of Nutrition and Metabolism, 2015
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin ConditionsJournal of Investigative Dermatology, 2014
- Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitisJournal of Allergy and Clinical Immunology, 2011
- The Burden of Atopic Dermatitis: Impact on the Patient, Family, and SocietyPediatric Dermatology, 2005